MedTrace Logo

SWitching to Abilify Trial (SWAT)

NCT00304616 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2009-12-17

No results posted yet for this study

Summary

To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration

Conditions

Interventions

DRUG

Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chang-Yoon Kim, Prof. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2006-06-30
Completion
2007-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304616 on ClinicalTrials.gov